Company Description
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer.
The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E.
eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Dr. Stephen T. Worland Ph.D. |
Contact Details
Address: 142 North Cedros Avenue, Suite B Solana Beach, California 92075 United States | |
| Phone | (858) 925-8215 |
| Website | effector.com |
Stock Details
| Ticker Symbol | EFTR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828522 |
| CUSIP Number | 28202V108 |
| ISIN Number | US28202V2079 |
| Employer ID | 85-3306396 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stephen T. Worland Ph.D. | Chief Executive Officer, President and Director |
| Michael Byrnes M.B.A. | Chief Financial Officer |
| Dr. Douglas Warner M.D. | Chief Medical Officer |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 4, 2024 | 424B3 | Prospectus |
| Apr 4, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 424B5 | Filing |
| Apr 2, 2024 | EFFECT | Notice of Effectiveness |
| Mar 29, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 25, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |